A day after the World Health Organisation (WHO) suspended the allocation of patients in the hydroxychloroquine (HCQ) arm of its multi-country Solidarity Trial to find an effective treatment for Covid-19, India reiterated its faith in the continued prophylactic use of the anti-malaria drug for the novel coronavirus disease.
There is enough experience in the country of using HCQ, and sufficient data from observational and case control studies to warrant its use, the government said.
HCQ also continues to be used for treatment of Covid-19, along with the antibiotic azithromycin. “We will review it,” Dr Balram Bhargava, DG, Indian Council of Medical Research (ICMR) and Secretary, Department of Health Research, said on Tuesday.
Leave a Reply